Market closedNon-fractionalADR
Innate Pharma/IPHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Innate Pharma
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Ticker
IPHA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Marseille, France
Employees
179
Website
www.innate-pharma.com
Innate Pharma Metrics
BasicAdvanced
$222M
Market cap
-
P/E ratio
-$0.10
EPS
0.36
Beta
-
Dividend rate
Price and volume
Market cap
$222M
Beta
0.36
52-week high
$3.57
52-week low
$1.81
Average daily volume
0.22
Financial strength
Current ratio
3.734
Long term debt to equity
146.408
Total debt to equity
178.359
Management effectiveness
Return on assets (TTM)
-3.86%
Return on equity (TTM)
-14.28%
Return on investment (TTM)
-4.87%
Valuation
Price to revenue (TTM)
3.938
Price to book
3.937
Price to tangible book (TTM)
3.97
Growth
Revenue change (TTM)
4.68%
Earnings per share change (TTM)
87.13%
3-year revenue growth
-2.59%
What the Analysts think about Innate Pharma
Analyst Ratings
Majority rating from 5 analysts.
Innate Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€17M
-53.26%
Net income
-€9.2M
-641.18%
Profit margin
-55.75%
-1,259.04%
Innate Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 22
Q4 22
Q2 23
Q4 23
Q2 24
Actual
€0.08
-€0.29
€0.02
-€0.11
-
Expected
-€0.15
-€0.39
-€0.14
-€0.32
-€0.28
Surprise
-154.55%
-25.64%
-114.29%
-65.63%
-
Innate Pharma News
AllArticlesVideos
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Business Wire·3 weeks ago
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
Business Wire·1 month ago
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innate Pharma stock?
Innate Pharma (IPHA) has a market cap of $222M as of July 06, 2024.
What is the P/E ratio for Innate Pharma stock?
The price to earnings (P/E) ratio for Innate Pharma (IPHA) stock is 0 as of July 06, 2024.
Does Innate Pharma stock pay dividends?
No, Innate Pharma (IPHA) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Innate Pharma dividend payment date?
Innate Pharma (IPHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innate Pharma?
Innate Pharma (IPHA) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Innate Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.